Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome

BACKGROUND: The BCN02-trial combined therapeutic vaccination with a viral latency reversing agent (romidepsin, RMD) in HIV-1-infected individuals and included a monitored antiretroviral pause (MAP) as an efficacy read-out identifying individuals with an early or late (< or > 4weeks) viral-rebo...

Descripción completa

Detalles Bibliográficos
Autores principales: Oriol-Tordera, Bruna, Esteve-Codina, Anna, Berdasco, María, Rosás-Umbert, Míriam, Gonçalves, Elena, Duran-Castells, Clara, Català-Moll, Francesc, Llano, Anuska, Cedeño, Samandhy, Puertas, Maria C., Tolstrup, Martin, Søgaard, Ole S., Clotet, Bonaventura, Martínez-Picado, Javier, Hanke, Tomáš, Combadiere, Behazine, Paredes, Roger, Hartigan-O'Connor, Dennis, Esteller, Manel, Meulbroek, Michael, Calle, María Luz, Sanchez-Pla, Alex, Moltó, José, Mothe, Beatriz, Brander, Christian, Ruiz-Riol, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938861/
https://www.ncbi.nlm.nih.gov/pubmed/35325780
http://dx.doi.org/10.1016/j.ebiom.2022.103956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938861/
https://www.ncbi.nlm.nih.gov/pubmed/35325780
http://dx.doi.org/10.1016/j.ebiom.2022.103956

Ejemplares similares